Financial Highlights - Revenues increased by 71% year-over-year, including Pro Farm's historical numbers for 1Q22[9] - Adjusted EBITDA almost doubled for the period[9] - Total revenues reached $127.1 million in 1Q23, a 71% increase compared to the pro forma $74.5 million in 1Q22[25] - Gross profit increased by 52% year-over-year[29] Business Developments - A long-term commercial and R&D agreement with Syngenta Seedcare was announced[9] - A $5 million share buyback was completed[9] - The Pro Farm merger was completed on July 12th[9] - Syngenta Seedcare paid $50 million upfront for rights granted under the collaboration agreement[20] HB4 Technology - HB4 wheat production in Argentina is estimated at 13.7 million metric tons, a 40% decrease compared to the previous season's 23 million metric tons[15] - Early season plantings of HB4 Soy are more than two times year-over-year[18] - The company anticipates HB4 Wheat to contribute $15-20 million in EBITDA by FY24 and HB4 Soy to contribute $20-25 million in EBITDA by FY25[39] Pro Farm Integration and Functional Currency Change - The integration of Pro Farm initiated on July 12th, 2022[13] - The functional currency was changed to USD in Argentine entities starting in FY23[22]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ◻ SHELL COMPANY REPORT PURSUANT TO SECTION ...

Exhibit 99.1 BIOCERES CROP SOLUTIONS CORP. Consolidated financial statements as of and for the years ended June 30, 2022, 2021 and 2020. ര Bioceres Crop Solutions Report of independent registered public accounting firm F-3 Consolidated statements of financial position F-4 Consolidated statements of comprehensive income F-6 Consolidated statements of changes in equity F-8 Consolidated statements of cash flows F-9 INDEX Consolidated financial statements as of and for the years ended June 30, 2022, 2021 and 20 ...

Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Q4 2022 Earnings Conference Call September 8, 2022 8:30 AM ET Company Participants Paula Savanti - Head of Investor Relations Federico Trucco - Chief Executive Officer Enrique López Lecube - Chief Financial Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Kemp Dolliver - Brookline Capital Markets Dmitry Silversteyn - Water Tower Research Operator Hello and welcome to the Bioceres Crop Solutions Fiscal Fourth Quarter 2022 Financial Resu ...

Financial Performance - Bioceres Crop Solutions achieved record comparable revenues for both Q4 2022 and FY22, with increases of 44% and 62% year-over-year, respectively[10] - Baseline Adjusted EBITDA reached $17.7 million for Q4 2022 and $61.9 million for the full year[10] - Total revenue reached $334.8 million for the fiscal year ended June 30, 2022, compared to $209.5 million in the previous fiscal year[39] - Gross profit was $126.5 million, with a gross profit percentage of 38%[39] HB4 Wheat - HB4 Wheat revenues amounted to $12.4 million, representing a 94% increase compared to the prior year's contributed goods number[11] - Gross margin for HB4 Wheat increased from 42% to 53%[14] Regulatory Approvals & Integration - Key regulatory clearances were obtained for HB4 Wheat and Soy from various countries, including the U.S., Australia, New Zealand, Nigeria, and China[11] - The merger with Marrone Bio Innovations, Inc, now ProFarm Group, was successfully completed[11] - The company is on track to deliver cost synergies of $8 million from the ProFarm integration[20] Balance Sheet - Total assets reached $518.3 million as of June 30, 2022[40] - Total liabilities amounted to $359.5 million[43] - The company executed financing agreements, including new secured convertible notes due in 2026, bringing in $55 million in proceeds[38]

Company Overview - Bioceres Crop Solutions is a fully-integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality[2] - The company has 44 years of experience in developing and commercializing products that enhance crop quality and productivity[3] - Bioceres completed a merger with Marrone Bio Innovations, creating a global leader in the agriculture biologicals market[3, 25] - The combined revenues of Bioceres and Marrone Bio Innovations are over $300 million, growing at a rate of over 20% CAGR over the past 4 years[25] Financial Performance - Bioceres Crop Solutions reported revenues of $2875 million for the last twelve months ended March 31, 2022[3, 4] - The Adjusted EBITDA for the same period was $613 million[4] - For the upcoming 2022/23 season, the company estimates revenues of approximately $10-12 million from HB4 Wheat[21] HB4 Technology - HB4 technology provides drought tolerance in soy-wheat cropping systems, leading to a 13% yield increase in soy and a 195% yield increase in wheat[6, 8] - The total addressable market for HB4 soy is estimated at ~30-35 million hectares, with a share of the total market of ~35-40%[8] - The total addressable market for HB4 wheat is estimated at ~25-3 million hectares, with a share of the total market of ~30-35%[8] Market and Regulatory Status - Regulatory approval for HB4 soy has been received in over 85% of the global soy market, including Argentina, Brazil, Canada, and the US[9, 10]

Investor Presentation NASDAQ: BIOX June 2022 ര Bioceres Crop Solutions Disclaimer | --- ...

Exhibit 99.1 BIOCERES CROP SOLUTIONS CORP. Unaudited interim condensed consolidated financial statements as of March 31, 2022 and June 30, 2021, and for the three-and nine-month periods ended March 31, 2022, and 2021. ര Bioceres Crop Solutions Unaudited interim condensed consolidated statements of financial position as of March 31, 2022 and June 30, 2021 F-3 Unaudited interim condensed consolidated statements of comprehensive income for the three and nine-month periods ended March 31, 2022 and 2021 F-5 Unau ...

Marrone Bio Innovations, Inc. (MBII) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Kevin Helash – Chief Executive Officer Linda Moore – Chief Legal Officer LaDon Johnson – Interim Chief Financial Officer Matti Tiainen – Senior Vice President International Sales Kamal El Mernissi – Senior Director of Product & Marketing Conference Call Participants Dmitry Silversteyn – Water Tower Research Operator Good afternoon ladies and gentlemen, and welcome to the First Quarter 2022 Earn ...

Financial Performance - Annual revenue increased from $38.4 million in 2020 to $44.3 million in 2021[4] - Gross profit margin improved from 59.6% in 2020 to 61.5% in 2021[8] - Adjusted EBITDA loss decreased from $(11.0) million in 2020 to $(8.7) million in 2021[6] - Operating expense ratio decreased from 104.4% in FY 2020 to 96.3% in FY 2021[9] Q4 2021 Results - Revenues increased by 40.2% from $7.7 million in Q4 2020 to $10.8 million in Q4 2021[12] - Gross profit increased by 31.5% from $4.9 million in Q4 2020 to $6.5 million in Q4 2021[12] - Adjusted EBITDA loss increased by 78.7% from $(2.2) million in Q4 2020 to $(4.0) million in Q4 2021[12] Cash Flow and Debt - Cash used in operations improved from $(16.0) million to $(10.0) million[10] - Ending cash increased by $3.8 million to $19.6 million[10] - Net debt increased by $1.7 million[10] Merger Highlights - The merger creates a combined revenue of +$300 million growing at a +20% CAGR over the past 4 years[11]